Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H23N5O2S2.ClH |
| Molecular Weight | 526.073 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.O=S(=O)(N1CC2=C(C=CC(=C2)C#N)N(CC3=CN=CN3)C[C@H]1CC4=CC=CC=C4)C5=CC=CS5
InChI
InChIKey=LBPFLNDUCNNGPS-GNAFDRTKSA-N
InChI=1S/C25H23N5O2S2.ClH/c26-13-20-8-9-24-21(11-20)15-30(34(31,32)25-7-4-10-33-25)23(12-19-5-2-1-3-6-19)17-29(24)16-22-14-27-18-28-22;/h1-11,14,18,23H,12,15-17H2,(H,27,28);1H/t23-;/m1./s1
Bristol-Myers Squibb developed BMS-214662 as potent and selective farnesyl transferase inhibitor with potent antitumor activity. BMS-214662 participated in phase II trials in the US for pancreatic, head and neck, lung and colorectal cancers. However, further information is not available.
Approval Year
Sample Use Guides
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
44189294
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY | |||
|
2ZRT8VWQ9J
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY | |||
|
195981-08-9
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY | |||
|
DBSALT002163
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
